513 related articles for article (PubMed ID: 17227635)
1. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a selective screening for colorectal carcinoma: the Taiwan Multicenter Cancer Screening (TAMCAS) project.
Chen TH; Yen MF; Lai MS; Koong SL; Wang CY; Wong JM; Prevost TC; Duffy SW
Cancer; 1999 Oct; 86(7):1116-28. PubMed ID: 10506694
[TBL] [Abstract][Full Text] [Related]
3. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
4. Limitations of the faecal occult blood test in screening for colorectal cancer.
Delcò F; Sonnenberg A
Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
[TBL] [Abstract][Full Text] [Related]
5. Evolution of multiple disease screening in Keelung: a model for community involvement in health interventions?
Wang PE; Wang TT; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S54-8. PubMed ID: 17227644
[TBL] [Abstract][Full Text] [Related]
6. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.
Kronborg O; Jørgensen OD; Fenger C; Rasmussen M
Scand J Gastroenterol; 2004 Sep; 39(9):846-51. PubMed ID: 15513382
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16).
Chen LS; Liao CS; Chang SH; Lai HC; Chen TH
J Med Screen; 2007; 14(4):191-9. PubMed ID: 18078564
[TBL] [Abstract][Full Text] [Related]
8. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.
Tsoi KK; Ng SS; Leung MC; Sung JJ
Aliment Pharmacol Ther; 2008 Aug; 28(3):353-63. PubMed ID: 18638075
[TBL] [Abstract][Full Text] [Related]
10. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
11. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
[TBL] [Abstract][Full Text] [Related]
12. Colorectal carcinoma: is screening possible?
Bonelli L
Tech Coloproctol; 2004 Dec; 8 Suppl 2():s267-72. PubMed ID: 15666104
[TBL] [Abstract][Full Text] [Related]
13. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M;
J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257
[TBL] [Abstract][Full Text] [Related]
14. Would general practitioners support a population-based colorectal cancer screening programme of faecal-occult blood testing?
Tong S; Hughes K; Oldenburg B; Del Mar C
Intern Med J; 2004; 34(9-10):532-8. PubMed ID: 15482265
[TBL] [Abstract][Full Text] [Related]
15. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
Musil D; Tillich J
Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
[TBL] [Abstract][Full Text] [Related]
16. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain).
Peris M; Espinàs JA; Muñoz L; Navarro M; Binefa G; Borràs JM;
J Med Screen; 2007; 14(2):81-6. PubMed ID: 17626707
[TBL] [Abstract][Full Text] [Related]
17. High participation rates are not necessary for cost-effective colorectal cancer screening.
Howard K; Salkeld G; Irwig L; Adelstein BA
J Med Screen; 2005; 12(2):96-102. PubMed ID: 15949121
[TBL] [Abstract][Full Text] [Related]
18. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
19. A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared with screening colonoscopy.
Haug U; Brenner H
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):422-8. PubMed ID: 15734968
[TBL] [Abstract][Full Text] [Related]
20. Screening for colorectal cancer.
Hakama M; Hoff G; Kronborg O; Påhlman L
Acta Oncol; 2005; 44(5):425-39. PubMed ID: 16118076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
